Zhi Rong Qian1,2, Douglas A Rubinson1, Jonathan A Nowak2,3, Vicente Morales-Oyarvide1, Richard F Dunne4, Margaret M Kozak5, Marisa W Welch1, Lauren K Brais1, Annacarolina Da Silva1,2, Tingting Li2, Wanwan Li2, Atsuhiro Masuda2, Juhong Yang2, Yan Shi2, Mancang Gu2, Yohei Masugi2, Justin Bui5, Caitlin L Zellers1, Chen Yuan1,6, Ana Babic1, Natalia Khalaf7, Andrew Aguirre1, Kimmie Ng1, Rebecca A Miksad8, Andrea J Bullock8, Daniel T Chang5, Jennifer F Tseng9, Thomas E Clancy10, David C Linehan11, Jennifer J Findeis-Hosey12, Leona A Doyle3, Aaron R Thorner1,13, Matthew Ducar3,13, Bruce Wollison13, Angelica Laing13, William C Hahn1,13, Matthew Meyerson1,3,13,14, Charles S Fuchs1, Shuji Ogino1,2,6,15, Jason L Hornick3, Aram F Hezel4, Albert C Koong16, Brian M Wolpin1. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 2. Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 4. Division of Hematology and Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. 5. Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California. 6. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 7. Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts. 8. Department of Hematology and Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 9. Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 10. Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 11. Department of Surgery, University of Rochester Medical Center, Rochester, New York. 12. Department of Pathology, University of Rochester Medical Center, Rochester, New York. 13. Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts. 14. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts. 15. Division of Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 16. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Abstract
IMPORTANCE: Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes. OBJECTIVE: To evaluate the alterations of the 4 main driver genes in pancreatic adenocarcinoma and patient outcomes after cancer resection. DESIGN, SETTING, AND PARTICIPANTS: This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013). Associations of driver gene alterations with disease-free survival (DFS) and overall survival (OS) were evaluated using Cox proportional hazards regression with estimation of hazard ratios (HRs) and 95% CIs and adjustment for age, sex, tumor characteristics, institution, and perioperative treatment. Data were collected September 9, 2012, to June 28, 2016, and analyzed December 17, 2016, to March 14, 2017. MAIN OUTCOMES AND MEASURES: The DFS and OS among patients with resected pancreatic adenocarcinoma. RESULTS: Of the 356 patients studied, 191 (53.7%) were men and 165 (46.3%) were women, with a median (interquartile range [IQR]) age of 67 (59.0-73.5) years. Patients with KRAS mutant tumors had worse DFS (median [IQR], 12.3 [6.7 -27.2] months) and OS (20.3 [11.3-38.3] months) compared with patients with KRAS wild-type tumors (DFS, 16.2 [8.9-30.5] months; OS, 38.6 [16.6-63.1] months) and had 5-year OS of 13.0% vs 30.2%. Particularly poor outcomes were identified in patients with KRAS G12D-mutant tumors, who had a median (IQR) OS of 15.3 (9.8-32.7) months. Patients whose tumors lacked CDKN2A expression had worse DFS (median, 11.5 [IQR, 6.2-24.5] months) and OS (19.7 [10.9-37.1] months) compared with patients who had intact CDKN2A (DFS, 14.8 [8.2-30.5] months; OS, 24.6 [14.1-44.6] months). The molecular status of SMAD4 was not associated with DFS or OS, whereas TP53 status was associated only with shorter DFS (HR, 1.33; 95% CI, 1.02-1.75; P = .04). Patients had worse DFS and OS if they had a greater number of altered driver genes. Compared with patients with 0 to 2 altered genes, those with 4 altered genes had worse DFS (HR, 1.79 [95% CI, 1.24-2.59; P = .002]) and OS (HR, 1.38 [95% CI, 0.98-1.94; P = .06]). Five-year OS was 18.4% for patients with 0 to 2 gene alterations, 14.1% for those with 3 alterations, and 8.2% for those with 4 alterations. CONCLUSIONS AND RELEVANCE: Patient outcomes are associated with alterations of the 4 main driver genes in resected pancreatic adenocarcinoma.
IMPORTANCE: Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes. OBJECTIVE: To evaluate the alterations of the 4 main driver genes in pancreatic adenocarcinoma and patient outcomes after cancer resection. DESIGN, SETTING, AND PARTICIPANTS: This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013). Associations of driver gene alterations with disease-free survival (DFS) and overall survival (OS) were evaluated using Cox proportional hazards regression with estimation of hazard ratios (HRs) and 95% CIs and adjustment for age, sex, tumor characteristics, institution, and perioperative treatment. Data were collected September 9, 2012, to June 28, 2016, and analyzed December 17, 2016, to March 14, 2017. MAIN OUTCOMES AND MEASURES: The DFS and OS among patients with resected pancreatic adenocarcinoma. RESULTS: Of the 356 patients studied, 191 (53.7%) were men and 165 (46.3%) were women, with a median (interquartile range [IQR]) age of 67 (59.0-73.5) years. Patients with KRAS mutant tumors had worse DFS (median [IQR], 12.3 [6.7 -27.2] months) and OS (20.3 [11.3-38.3] months) compared with patients with KRAS wild-type tumors (DFS, 16.2 [8.9-30.5] months; OS, 38.6 [16.6-63.1] months) and had 5-year OS of 13.0% vs 30.2%. Particularly poor outcomes were identified in patients with KRAS G12D-mutant tumors, who had a median (IQR) OS of 15.3 (9.8-32.7) months. Patients whose tumors lacked CDKN2A expression had worse DFS (median, 11.5 [IQR, 6.2-24.5] months) and OS (19.7 [10.9-37.1] months) compared with patients who had intact CDKN2A (DFS, 14.8 [8.2-30.5] months; OS, 24.6 [14.1-44.6] months). The molecular status of SMAD4 was not associated with DFS or OS, whereas TP53 status was associated only with shorter DFS (HR, 1.33; 95% CI, 1.02-1.75; P = .04). Patients had worse DFS and OS if they had a greater number of altered driver genes. Compared with patients with 0 to 2 altered genes, those with 4 altered genes had worse DFS (HR, 1.79 [95% CI, 1.24-2.59; P = .002]) and OS (HR, 1.38 [95% CI, 0.98-1.94; P = .06]). Five-year OS was 18.4% for patients with 0 to 2 gene alterations, 14.1% for those with 3 alterations, and 8.2% for those with 4 alterations. CONCLUSIONS AND RELEVANCE: Patient outcomes are associated with alterations of the 4 main driver genes in resected pancreatic adenocarcinoma.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch Journal: Ann Surg Date: 2002-01 Impact factor: 12.969
Authors: Shinichi Yachida; Catherine M White; Yoshiki Naito; Yi Zhong; Jacqueline A Brosnan; Anne M Macgregor-Das; Richard A Morgan; Tyler Saunders; Daniel A Laheru; Joseph M Herman; Ralph H Hruban; Alison P Klein; Siân Jones; Victor Velculescu; Christopher L Wolfgang; Christine A Iacobuzio-Donahue Journal: Clin Cancer Res Date: 2012-09-18 Impact factor: 12.531
Authors: Vicente Valero; Tyler J Saunders; Jin He; Matthew J Weiss; John L Cameron; Avani Dholakia; Aaron T Wild; Eun Ji Shin; Mouen A Khashab; Anne Marie O'Broin-Lennon; Syed Z Ali; Daniel Laheru; Ralph H Hruban; Christine A Iacobuzio-Donahue; Joseph M Herman; Christopher L Wolfgang Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Kimberly Perez; Thomas E Clancy; Joseph D Mancias; Michael H Rosenthal; Brian M Wolpin Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban Journal: Clin Cancer Res Date: 2009-07-07 Impact factor: 12.531
Authors: Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; Hirohiko Kamiyama; Antonio Jimeno; Seung-Mo Hong; Baojin Fu; Ming-Tseh Lin; Eric S Calhoun; Mihoko Kamiyama; Kimberly Walter; Tatiana Nikolskaya; Yuri Nikolsky; James Hartigan; Douglas R Smith; Manuel Hidalgo; Steven D Leach; Alison P Klein; Elizabeth M Jaffee; Michael Goggins; Anirban Maitra; Christine Iacobuzio-Donahue; James R Eshleman; Scott E Kern; Ralph H Hruban; Rachel Karchin; Nickolas Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Agnieszka K Witkiewicz; Elizabeth A McMillan; Uthra Balaji; GuemHee Baek; Wan-Chi Lin; John Mansour; Mehri Mollaee; Kay-Uwe Wagner; Prasad Koduru; Adam Yopp; Michael A Choti; Charles J Yeo; Peter McCue; Michael A White; Erik S Knudsen Journal: Nat Commun Date: 2015-04-09 Impact factor: 14.919
Authors: Ritu R Singh; Johanna Goldberg; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly Journal: Cancer Treat Rev Date: 2019-03-22 Impact factor: 12.111
Authors: Caitlin A McIntyre; Sharon A Lawrence; Allison L Richards; Joanne F Chou; Winston Wong; Marinela Capanu; Michael F Berger; Mark T A Donoghue; Kenneth H Yu; Anna M Varghese; David P Kelsen; Wungki Park; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Christine A Iacobuzio-Donahue; Peter J Allen; Eileen M O'Reilly Journal: Cancer Date: 2020-06-23 Impact factor: 6.860
Authors: Katherine Minjee Chung; Jaffarguriqbal Singh; Lauren Lawres; Kimberly Judith Dorans; Cathy Garcia; Daniel B Burkhardt; Rebecca Robbins; Arjun Bhutkar; Rebecca Cardone; Xiaojian Zhao; Ana Babic; Sara A Vayrynen; Andressa Dias Costa; Jonathan A Nowak; Daniel T Chang; Richard F Dunne; Aram F Hezel; Albert C Koong; Joshua J Wilhelm; Melena D Bellin; Vibe Nylander; Anna L Gloyn; Mark I McCarthy; Richard G Kibbey; Smita Krishnaswamy; Brian M Wolpin; Tyler Jacks; Charles S Fuchs; Mandar Deepak Muzumdar Journal: Cell Date: 2020-04-17 Impact factor: 41.582
Authors: Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Ashton A Connor; Robert E Denroche; Gun Ho Jang; Mathieu Lemire; Amy Zhang; Michelle Chan-Seng-Yue; Gavin Wilson; Robert C Grant; Daniele Merico; Ilinca Lungu; John M S Bartlett; Dianne Chadwick; Sheng-Ben Liang; Jenna Eagles; Faridah Mbabaali; Jessica K Miller; Paul Krzyzanowski; Heather Armstrong; Xuemei Luo; Lars G T Jorgensen; Joan M Romero; Prashant Bavi; Sandra E Fischer; Stefano Serra; Sara Hafezi-Bakhtiari; Derin Caglar; Michael H A Roehrl; Sean Cleary; Michael A Hollingsworth; Gloria M Petersen; Sarah Thayer; Calvin H L Law; Sulaiman Nanji; Talia Golan; Alyssa L Smith; Ayelet Borgida; Anna Dodd; David Hedley; Bradly G Wouters; Grainne M O'Kane; Julie M Wilson; George Zogopoulos; Faiyaz Notta; Jennifer J Knox; Steven Gallinger Journal: Cancer Cell Date: 2019-01-24 Impact factor: 31.743
Authors: Matthew B Yurgelun; Anu B Chittenden; Vicente Morales-Oyarvide; Jonathan A Nowak; Brian M Wolpin; Douglas A Rubinson; Richard F Dunne; Margaret M Kozak; Zhi Rong Qian; Marisa W Welch; Lauren K Brais; Annacarolina Da Silva; Justin L Bui; Chen Yuan; Tingting Li; Wanwan Li; Atsuhiro Masuda; Mancang Gu; Andrea J Bullock; Daniel T Chang; Thomas E Clancy; David C Linehan; Jennifer J Findeis-Hosey; Leona A Doyle; Aaron R Thorner; Matthew D Ducar; Bruce M Wollison; Natalia Khalaf; Kimberly Perez; Sapna Syngal; Andrew J Aguirre; William C Hahn; Matthew L Meyerson; Charles S Fuchs; Shuji Ogino; Jason L Hornick; Aram F Hezel; Albert C Koong Journal: Genet Med Date: 2018-07-02 Impact factor: 8.822
Authors: Miquel Porta; José Pumarega; André F S Amaral; Jeanine M Genkinger; Judit Camargo; Lorelei Mucci; Juan Alguacil; Magda Gasull; Xuehong Zhang; Eva Morales; Mar Iglesias; Shuji Ogino; Lawrence S Engel Journal: Environ Res Date: 2020-06-11 Impact factor: 6.498